Granules India Ltd
NSE:GRANULES

Watchlist Manager
Granules India Ltd Logo
Granules India Ltd
NSE:GRANULES
Watchlist
Price: 596.85 INR 1.73%
Market Cap: 144.7B INR
Have any thoughts about
Granules India Ltd?
Write Note

Granules India Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Granules India Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Granules India Ltd
NSE:GRANULES
Accounts Receivables
â‚ą9.9B
CAGR 3-Years
8%
CAGR 5-Years
5%
CAGR 10-Years
22%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Accounts Receivables
â‚ą84.4B
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Accounts Receivables
â‚ą55.9B
CAGR 3-Years
17%
CAGR 5-Years
7%
CAGR 10-Years
13%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Accounts Receivables
â‚ą129.4B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
14%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Accounts Receivables
â‚ą17.8B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
4%
M
Mankind Pharma Ltd
NSE:MANKIND
Accounts Receivables
â‚ą8.5B
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Granules India Ltd
Glance View

Market Cap
144.7B INR
Industry
Pharmaceuticals

In the bustling corridors of the pharmaceutical world, Granules India Ltd. has carved out a distinctive niche through its unwavering commitment to efficiencies and economies of scale. Founded in 1984, the company began its journey as an operator of a small Paracetamol facility and steadily evolved into a formidable player on the global stage. Granules India's business model is streamlined; it meticulously integrates its manufacturing processes, focusing primarily on Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosage Forms (FDFs). By leveraging vertically integrated operations, the company ensures a seamless transition from raw material to finished product, reducing costs while maintaining high standards of product quality, an achievement that distinguishes it in the competitive landscape. Granules India capitalizes on its robust manufacturing infrastructure, which operates round the clock to serve a diverse clientele spanning across regulated and semi-regulated markets. This emphasis on cost-effective production is coupled with strategic geographical placement of its facilities, allowing it to cater efficiently to domestic and international markets, including North America, Europe, and emerging economies. The company's revenue streams are largely driven by the sales of its extensive product portfolio, which includes key therapeutic areas like over-the-counter (OTC) brands and prescription medications. By maintaining a diversified product line and emphasizing high-volume, low-margin products, Granules India continually fortifies its market position while sustaining a healthy balance between growth and stability.

GRANULES Intrinsic Value
456.52 INR
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Granules India Ltd's Accounts Receivables?
Accounts Receivables
9.9B INR

Based on the financial report for Sep 30, 2024, Granules India Ltd's Accounts Receivables amounts to 9.9B INR.

What is Granules India Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
22%

Over the last year, the Accounts Receivables growth was -3%. The average annual Accounts Receivables growth rates for Granules India Ltd have been 8% over the past three years , 5% over the past five years , and 22% over the past ten years .

Back to Top